The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure

Haematologica. 2016 Jun;101(6):e224-7. doi: 10.3324/haematol.2015.140962. Epub 2016 Mar 18.

¹ Leukemia Program and Department of Translational Hematology and Oncology Research, Cleveland Clinic, OH, USA.
² Department of Malignant Hematology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.
³ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁴ Department of Quantitative Health Sciences, Cleveland Clinic, OH, USA.
⁵ Division of Hematology and Oncology, New York Presbyterian Hospital-Weill Cornell Medical College, NY, USA.
⁶ Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁷ Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
⁸ Leukemia Program and Department of Translational Hematology and Oncology Research, Cleveland Clinic, OH, USA sekerem@ccf.org.

No abstract available

Keywords: MDS; hypomethylating agent; prognostic models.

Publication types